Effectiveness of the 23-valent Polysaccharide Pneumococcal Vaccine Against Invasive Pneumococcal Disease in People 60 Years or Older

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2010 Mar 20

PMID 20298596

Citations 25

Authors

Angel Vila-Corcoles

Olga Ochoa-Gondar

Jorge A Guzman

Teresa Rodriguez-Blanco

Elisabet Salsench

Cruz M Fuentes

Affiliations

Soon will be listed here.

Abstract

Background: The 23-valent polysaccharide pneumococcal vaccine (PPV) is currently recommended in elderly and high-risk adults. However, its efficacy in preventing pneumococcal infections remains controversial. This study assessed the clinical effectiveness of vaccination against invasive pneumococcal disease (IPD) among people over 60 years.

Methods: Population-based case-control study that included 88 case patients over 60 years-old with a laboratory-confirmed IPD (bacteraemic pneumonia, meningitis or sepsis) and 176 outpatient control subjects who were matched by primary care centre, age, sex and risk stratum. Adjusted odds ratios (ORs) for vaccination were calculated using conditional logistic regression, controlling for underlying conditions. Vaccine effectiveness was estimated as (1 - OR) x100.

Results: Pneumococcal vaccination rate was significantly lower in cases than in control subjects (38.6% vs 59.1%; p = 0.002). The adjusted vaccine effectiveness was 72% (OR: 0.28; 95% CI: 0.15-0.54) against all IPD and 77% (OR: 0.23; 95% CI: 0.08-0.60) against vaccine-type IPD. Vaccination was significantly effective against all IPD in both age groups: 60-79 years-old (OR 0.32; 95% CI: 0.14-0.74) and people 80 years or older (OR: 0.29; 95% CI: 0.09-0.91). Vaccination appears significantly effective as for high-risk immunocompetent subjects (OR: 0.29; 95% CI: 0.11-0.79) as well as for immunocompromised subjects (OR: 0.12; 95% CI: 0.03-0.53).

Conclusion: These findings confirm the effectiveness of the 23-valent PPV against IPD, and they also support the benefit of vaccination in preventing invasive infections among high-risk and older people.

Citing Articles

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.

Nielsen K, Nielsen L, Dalby T, Lomholt F, Slotved H, Fuursted K Emerg Infect Dis. 2024; 30(6):1164-1172.

PMID: 38781925 PMC: 11138992. DOI: 10.3201/eid3006.230975.

Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales.

Djennad A, Ramsay M, Pebody R, Fry N, Sheppard C, Ladhani S EClinicalMedicine. 2019; 6:42-50.

PMID: 31193709 PMC: 6537583. DOI: 10.1016/j.eclinm.2018.12.007.

Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports.

Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Azimzadeh Jamalkandi S, Ahmadi A Sci Rep. 2018; 8(1):11051.

PMID: 30038423 PMC: 6056566. DOI: 10.1038/s41598-018-29280-2.

Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.

Yu J, Li B, Chen X, Lu J, Wang D, Gu T Infect Immun. 2018; 86(6).

PMID: 29610257 PMC: 5964518. DOI: 10.1128/IAI.00916-17.

[Vaccination in advanced age].

Heppner H, Leischker A, Wutzler P, Kwetkat A Internist (Berl). 2017; 59(2):205-212.

PMID: 29230484 DOI: 10.1007/s00108-017-0358-1.

References

Hutchison B, Oxman A, Shannon H, Lloyd S, Altmayer C, Thomas K . Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician. 1999; 45:2381-93. PMC: 2328641. View

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A . Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009; 27(10):1504-10. DOI: 10.1016/j.vaccine.2009.01.013. View

Watson L, Wilson B, Waugh N . Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine. 2002; 20(17-18):2166-73. DOI: 10.1016/s0264-410x(02)00112-3. View

Mangtani P, Cutts F, Hall A . Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003; 3(2):71-8. DOI: 10.1016/s1473-3099(03)00514-0. View

Jackson L, Neuzil K, Yu O, Benson P, Barlow W, Adams A . Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003; 348(18):1747-55. DOI: 10.1056/NEJMoa022678. View

Moore R, Wiffen P, Lipsky B . Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract. 2000; 1:1. PMC: 29074. DOI: 10.1186/1471-2296-1-1. View

Abraham-Van Parijs B . Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine. 2004; 22(11-12):1362-71. DOI: 10.1016/j.vaccine.2004.01.029. View

Bogaert D, Hermans P, Adrian P, Rumke H, de Groot R . Pneumococcal vaccines: an update on current strategies. Vaccine. 2004; 22(17-18):2209-20. DOI: 10.1016/j.vaccine.2003.11.038. View

Fedson D, Liss C . Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine. 2004; 22(8):927-46. DOI: 10.1016/j.vaccine.2003.09.027. View

10.

Melegaro A, Edmunds W . The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol. 2004; 19(4):353-63. DOI: 10.1023/b:ejep.0000024701.94769.98. View

11.

Conaty S, Watson L, Dinnes J, Waugh N . The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine. 2004; 22(23-24):3214-24. DOI: 10.1016/j.vaccine.2003.08.050. View

12.

Riley I, Tarr P, Andrews M, Pfeiffer M, Howard R, Challands P . Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet. 1977; 1(8026):1338-41. DOI: 10.1016/s0140-6736(77)92552-1. View

13.

Smit P, OBERHOLZER D, HAYDEN-SMITH S, Koornhof H, HILLEMAN M . Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977; 238(24):2613-6. View

14.

Shapiro E, Clemens J . A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984; 101(3):325-30. DOI: 10.7326/0003-4819-101-3-325. View

15.

Sims R, Steinmann W, McConville J, King L, Zwick W, Schwartz J . The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988; 108(5):653-7. DOI: 10.7326/0003-4819-108-5-653. View

16.

Fine M, Smith M, Carson C, Meffe F, Sankey S, Weissfeld L . Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med. 1994; 154(23):2666-77. DOI: 10.1001/archinte.1994.00420230051007. View

17.

Farr B, Johnston B, Cobb D, Fisch M, Germanson T, Adal K . Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995; 155(21):2336-40. View

18.

. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-8):1-24. View

19.

Sisk J, Moskowitz A, Whang W, Lin J, Fedson D, McBean A . Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 1997; 278(16):1333-9. View

20.

Hausdorff W, Feikin D, Klugman K . Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5(2):83-93. DOI: 10.1016/S1473-3099(05)01280-6. View